EMA Authorised: Nilemdo (bempedoic acid) — Daiichi Sankyo Europe GmbH

View source ↗

Summary

The European Medicines Agency authorised Nilemdo (bempedoic acid) for hypercholesterolemia and related dyslipidemias. The marketing authorisation holder is Daii…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemias
• Hypercholesterolemia

Drugs mentioned

• Nilemdo (bempedoic acid)

Snippet

Status: Authorised. Therapeutic area: Hypercholesterolemia;Dyslipidemias. MAH: Daiichi Sankyo Europe GmbH. Decision date: 15/01/2026